Symbols

DMK(Delisted)

DMK Pharmaceuticals·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DMK

Dmk Pharmaceuticals Corporation

A clinical-stage neurobiotechnology company

Industry

Established Date

06/06/2006

Listing Date

12/13/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.adamispharmaceuticals.com

Security Type

Common stock

Office address

11682 El Camino Real, Suite 300, San Diego, CA 92130

Business

Introduction

DMK Pharmaceuticals Corporation was established on June 6, 2006 as a Delaware corporation. The company is an emerging pharmaceutical company that combines specialty pharmaceuticals and biotechnology to deliver innovative medicines to patients and physicians. The professional pharmaceutical products within the group mainly include some products under development in the allergy and respiratory markets, such as dry powder inhaler technology, which the company is currently applying for a special license and acquiring from 3M. The company's goal is to create low-cost treatments to replace existing treatments.

Company Financials

EPS

DMK has released its 2023 Q3 earnings. EPS was reported at -0.2, versus the expected 0, missing expectations. The chart below visualizes how DMK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DMK has released its 2023 Q3 earnings report, with revenue of 9.06K, reflecting a YoY change of -99.40%, and net profit of -1.39M, showing a YoY change of 68.45%. The Sankey diagram below clearly presents DMK's revenue sources and cost distribution.